CHICAGO–(Business enterprise WIRE)–MAIA Biotechnology, Inc. (NYSE American: MAIA) declared these days the advancement of its Telomere-Focusing on Molecule Software (“Project T3”). MAIA is designing and evaluating several telomere-concentrating on compounds made to modify the telomeric construction by way of the cancer mobile – intrinsic telomerase exercise – and so trigger the dying of these cells. The studies, executed in vitro in numerous most cancers mobile traces and in vivo in quite a few pre-scientific cancer types, shown the supposed mechanism of action and substantial-amount anti-most cancers activity for these new molecules. The compounds belong to a new chemical class of molecules named telomere targeting divalent dinucleotides.
MAIA has nominated 1 guide new molecular entity prospect (selected as MAIA-2021-20) and just one again-up new molecular entity applicant (MAIA-2022-12) for even further progression into preclinical GLP-toxicity and other studies, and may possibly progress one of these candidates into human medical trials on completion of the essential preclinical evaluations. MAIA also has submitted a broad provisional patent application covering the composition of issue for the new telomere-targeting molecules in the fourth quarter of 2022.
“The discovery and preclinical advancement of these new telomere-concentrating on compounds signify the beginning of a important new chapter for MAIA,” stated Sergei Gryaznov, Ph.D., MAIA Main Scientific Officer. “We have generated really encouraging knowledge in vitro and in vivo in numerous distinct tumor designs displaying outstanding solitary-agent action for the new compounds, as well as in mixture with immune checkpoint inhibitors. The observed anti-cancer activity is really extraordinary, often primary to total tumor eliminations in in vivo versions. We are doing the job diligently to progress these candidates towards clinical advancement.”
“Project T3 is a significant action ahead as we are creating novel direct telomere-altering compounds,” mentioned MAIA Chairman and Main Govt Officer Vlad Vitoc, M.D. “We are advancing a number of compounds by means of in depth preclinical enhancement as prospective abide by-on candidates to our direct therapeutic candidate, THIO, which is at the moment remaining evaluated in a Period 2 trial (THIO-101 trial) in clients with Non-Tiny Mobile Lung Cancer. We appear ahead to announcing additional developments of MAIA’s proprietary new molecular entity candidates in 2023 and past.”
At the XXIV International Spherical Table on Nucleosides, Nucleotides, and Nucleic Acids in Stockholm in August 2022, MAIA presented an overview of its promising THIO drug discovery platform for producing prospective anti-most cancers brokers. The presentation demonstrated the relevance of cancer cell telomeric DNA structural and useful integrity, as very well as therapeutically eye-catching prospect to induce worry, improve innate sensing and adaptive anti-tumor immunity by using “cancer cell self-produced” chemical modification of telomeres.
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a telomere-targeting agent at the moment in scientific growth to assess its activity in non-smaller cell lung most cancers (NSCLC), in sequential administration with LIBTAYO® (cemiplimab) an anti-PD1 therapy, created and commercialized by Regeneron. Telomeres perform a fundamental job in the survival of cancer cells and their resistance to present-day therapies. THIO is getting created as a next or higher line of treatment method for NSCLC for patients that have progressed past the common-of-treatment regimen of existing checkpoint inhibitors.
About MAIA Biotechnology, Inc.
MAIA is a medical-phase biopharmaceutical business producing focused immunotherapies for most cancers. The Company’s guide program is THIO, a likely initial-in-course most cancers telomere targeting agent in clinical progress for the therapy of clients with telomerase-good cancers. For far more information, make sure you visit www.maiabiotech.com.
Ahead Hunting Statements
This press launch contains forward-wanting statements such as, but not limited to, statements associated to the closing of the featuring and the envisioned use of proceeds, improvement of drug candidates, our operations and organization approach, our expected monetary benefits, and corporate updates. The forward-looking statements contained in this press launch are primarily based on management’s present-day expectations and are subject matter to substantial risks, uncertainty and improvements in situations. Precise benefits may well vary materially from these expressed by these expectations owing to challenges and uncertainties, which includes, amongst other people, individuals connected to our skill to acquire extra capital on favorable phrases to us, or at all, like, without limitation, to fund our latest and foreseeable future preclinical scientific studies and scientific trials and the accomplishment, timing and price of our drug enhancement method and our ongoing or foreseeable future preclinical reports and medical trials, which include, with out limitation, the likelihood of unfavorable new clinical and preclinical facts and further analyses of existing information, that the challenges that prior scientific and preclinical effects may perhaps not be replicated, and risks connected with the present-day coronavirus pandemic. Ahead-searching statements converse only as of the date of this push release, and we undertake no obligation to assessment or update any ahead-on the lookout statement apart from as may possibly be required by applicable legislation.